The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

📢It’s #WorldCancerResearchDay!

➡️Head over to http://VJOncology.com to explore exciting updates in the latest clinical trials!

⭐Whilst you’re there, make sure to check out some of the cutting-edge research presented at #ESMO22 just last week!

@myESMO @VJOncology

Reply on Twitter 1573779477276024833Retweet on Twitter 15737794772760248331Like on Twitter 15737794772760248331Twitter 1573779477276024833
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

📢http://VJOncology.com has roundtable discussions featuring leading experts of #LungCancer, #BreastCancer, and more!

⭐Listen as they discuss key issues in cancer research in light of #WorldCancerResearchDay

➡️http://ow.ly/ixbX50KQh5s⬅️

#Oncology #VJSession @VJOncology

Reply on Twitter 1573704378938265601Retweet on Twitter 1573704378938265601Like on Twitter 15737043789382656011Twitter 1573704378938265601
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

🎥 @david_tougeron of Poitiers University Hospital discusses DURIGAST: 2L FOLFIRI plus durvalumab plus tremelimumab in gastric or GEJ cancer

Watch: 👉http://ow.ly/RBmH50KQzCP👈

@myESMO #ESMO22

Reply on Twitter 1573704374441938944Retweet on Twitter 15737043744419389443Like on Twitter 15737043744419389443Twitter 1573704374441938944
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

📢Check out some of the highlights from ASCO 2022 over at http://VJOncology.com, including key updates in clinical trials generating improved outcomes for patients worldwide.

📖Read here ➡️http://ow.ly/PO4s50KQgfE⬅️

#WorldCancerResearchDay @ASCO @VJOncology #ASCO22 #Oncology

Reply on Twitter 1573674242524209157Retweet on Twitter 1573674242524209157Like on Twitter 1573674242524209157Twitter 1573674242524209157
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

We’re here to bring you the highlights of what experts have been discussing on the second day of #NACLC22! 🙌

Check out http://VJOncology.com to discover more about what experts have discussed so far in the field of #LungCancer.

@VJOncology @IASLC #LCSM #NSCLC #SCLC

Reply on Twitter 1573658869892530176Retweet on Twitter 1573658869892530176Like on Twitter 1573658869892530176Twitter 1573658869892530176
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

📢It’s #WorldCancerResearchDay!

➡️Head over to http://VJOncology.com to explore exciting updates in the latest clinical trials!

⭐Whilst you’re there, make sure to check out some of the cutting-edge research presented at #ESMO22 just last week!

@myESMO @VJOncology

Reply on Twitter 1573779477276024833Retweet on Twitter 15737794772760248331Like on Twitter 15737794772760248331Twitter 1573779477276024833
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

📢http://VJOncology.com has roundtable discussions featuring leading experts of #LungCancer, #BreastCancer, and more!

⭐Listen as they discuss key issues in cancer research in light of #WorldCancerResearchDay

➡️http://ow.ly/ixbX50KQh5s⬅️

#Oncology #VJSession @VJOncology

Reply on Twitter 1573704378938265601Retweet on Twitter 1573704378938265601Like on Twitter 15737043789382656011Twitter 1573704378938265601
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

🎥 @david_tougeron of Poitiers University Hospital discusses DURIGAST: 2L FOLFIRI plus durvalumab plus tremelimumab in gastric or GEJ cancer

Watch: 👉http://ow.ly/RBmH50KQzCP👈

@myESMO #ESMO22

Reply on Twitter 1573704374441938944Retweet on Twitter 15737043744419389443Like on Twitter 15737043744419389443Twitter 1573704374441938944
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

📢Check out some of the highlights from ASCO 2022 over at http://VJOncology.com, including key updates in clinical trials generating improved outcomes for patients worldwide.

📖Read here ➡️http://ow.ly/PO4s50KQgfE⬅️

#WorldCancerResearchDay @ASCO @VJOncology #ASCO22 #Oncology

Reply on Twitter 1573674242524209157Retweet on Twitter 1573674242524209157Like on Twitter 1573674242524209157Twitter 1573674242524209157
VJOncologyVJ Oncology@VJOncology·
September 24, 2022

We’re here to bring you the highlights of what experts have been discussing on the second day of #NACLC22! 🙌

Check out http://VJOncology.com to discover more about what experts have discussed so far in the field of #LungCancer.

@VJOncology @IASLC #LCSM #NSCLC #SCLC

Reply on Twitter 1573658869892530176Retweet on Twitter 1573658869892530176Like on Twitter 1573658869892530176Twitter 1573658869892530176
Load More

Late-Breaking Abstracts at ASCO 2022!

View all
1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
2:18
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022

Latest videos from ASCO 2022

View all
1:32
Key trials in prostate cancer at ASCO 2022
Arun Azad • 27 May 2022
2:35
Adjuvant therapy in RCC: harnessing prognostic information
Pavlos Msaouel • 3 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022

Breast Cancer at ASCO 2022

View all
0:51
What to look forward to in breast cancer at ASCO 2022?
Kevin Kalinsky • 3 Jun 2022
0:53
postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapy
Kevin Kalinsky • 3 Jun 2022
1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022
0:48
MAINTAIN: fulvestrant or exemestane +/- ribociclib after anti-estrogen therapy + CDK4/6i in HR+ MBC
Kevin Kalinsky • 3 Jun 2022

GU at ASCO 2022

View all
1:32
Key trials in prostate cancer at ASCO 2022
Arun Azad • 27 May 2022
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022
2:18
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:12
JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer
Joaquim Bellmunt • 4 Jun 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals